Kaiseraugst (Switzerland), October 3, 2023
Following the merger of two iconic companies – DSM and Firmenich – in May 2023, dsm-firmenich will make its debut at CPHI Barcelona 2023, showcasing its combined strength as an innovator in health, nutrition and care. The company, which has shared sales of more than €12 billion and a workforce of almost 30,000 employees, will demonstrate how its growing portfolio of high-quality products, customized solutions and expert services are poised to fuel purpose-driven innovation in the pharmaceutical industry. With a longstanding history as one of the earliest suppliers of vitamins for pharmaceutical applications, advanced science, ingredient excellence and innovative technologies, dsmfirmenich will highlight the heritage that cements its position as a trusted partner in the industry. It will spotlight how it is addressing critical challenges across the landscape – including those related to cannabinoid formulation, nitrosamine risk mitigation and drug delivery systems. To delve deeper into these topics and beyond, join experts on booth 7P50 (API hall 7).
dsm-firmenich will illuminate how it is breaking new boundaries in the cannabinoid arena to pave the way for the pharmaceutical industry’s need for more patient-centric formulations. Taking center stage is the company’s high-purity, GMP-certified cannabinoid API portfolio and unique innovation platform – developed in collaboration with strategic partner, Brains Bioceutical. dsm-firmenich will unveil why and how it is set to revolutionize drug development in the cannabinoid space, emphasizing new, proprietary data that supports customizable drug formulation strategies for solid oral dosage formats and bioavailability enhancement.
Alexandru Zabara, Innovation Manager Pharma and Medical Nutrition at dsm-firmenich, explains: "Our aim is to expand treatment options and convenience for patients worldwide. We have invested in research to develop a unique drug delivery technology platform that will empower companies to enter the cannabinoid market with IP-protected solid oral dosage formulations boasting high drug loading, stability, and superior bioavailability. We’ll be unveiling the promising preliminary findings of our investigation at the show.”
Visitors can also learn how dsm-firmenich is helping to address critical market needs, like nitrosamine risk mitigation. “Nitrosamine contamination continues to be a pressing matter in the pharma industry,” says Zdravka Misic, Principal Scientist EMEA, dsm-firmenich. “We have a portfolio of antioxidants of the high quality available to support an FDA-recommended strategy for nitrosamine risk mitigation – ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E). New data and insights substantiate the proof of concept and the potential of antioxidant excipients as nitrosamine blocking agents. We look forward to discussing with our existing customers and potential new partners how we can support with risk assessment, formulation expertise and application knowledge in the space.”
dsm-firmenich’s broad vitamin API portfolio and growing specialty excipients offering will be highlighted at the show, demonstrating why dsm-firmenich is the partner of choice for ingredients of outstanding quality, reliable and sustainable supply, paired with technical, and regulatory and quality expertise, meeting the needs of the market and brining customers confidence and peace of mind. During the event, attendees will have the unique opportunity to explore how the recent merger expanded the company’s specialty excipient offering to include co-creation opportunities for taste-masking, flavors and more.
A testament to its industry-leading sustainability values, dsm-firmenich has launched a new Sustainability Imp’Act Card™ program, supporting its robust product portfolio. Kelsey Achenbach, Vice President Pharma & Medical Nutrition, comments: “Each card displays tangible, transparent insights into the environmental and social impact of our ingredients – underlying how our broad offering can enable partners to distinguish themselves in the market with environmentally-conscious pharmaceuticals.” dsm-firmenich has earned a spot on the shortlist in the CPHI Awards 2023 sustainability category, underscoring its dedication to a greener future.
For the biomedical domain, the company will spotlight TheraPEA™, a breakthrough polymer technology for advanced sustained-release drug products. Demonstrating dsm-firmenich’s leading polymer expertise, the revolutionary biodegradable platform addresses limitations associated with traditional polymeric materials, empowering the formulation of small molecule drugs and biologics for parenteral drug delivery.
Research and innovation are the key components powering the pharmaceutical sector's growth by creating new therapies that treat diseases and help improve people's quality of life. To inspire a platform fully dedicated to innovation, dsm-firmenich will host an exclusive reception on 24 October – the first day of CPHI. Featuring expert talks by IQVIA and KPMG representatives, attendees will gain insights into global trends, types of innovation and key elements of a robust innovation pipeline, aimed at maximizing impact across the pharmaceutical sector. Furthermore, the event will discuss patient pathways with key milestones and levers for success in drug development and highlight sustained release polymer technologies.
For more information about dsm-firmenich’s evolving, impactful pharmaceutical solutions, visit stand 7P50 at CPHI. Register your interest ahead of the event here.
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life™ every day, everywhere, for billions of people.
DSM Pharma Solutions
Barrett Dixon Bell
DSM Pharma Solutions
This press release may contain forward-looking statements with respect to dsm-firmenich’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. The English language version of this press release prevails over other language versions.